EP0244427A1 - Recombinant virus - Google Patents
Recombinant virusInfo
- Publication number
- EP0244427A1 EP0244427A1 EP86905164A EP86905164A EP0244427A1 EP 0244427 A1 EP0244427 A1 EP 0244427A1 EP 86905164 A EP86905164 A EP 86905164A EP 86905164 A EP86905164 A EP 86905164A EP 0244427 A1 EP0244427 A1 EP 0244427A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- polypeptide
- virus
- antigen
- recombinant
- vaccinia virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 62
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 75
- 229920001184 polypeptide Polymers 0.000 claims abstract description 69
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 69
- 230000002163 immunogen Effects 0.000 claims abstract description 17
- 239000012528 membrane Substances 0.000 claims abstract description 17
- 108091026890 Coding region Proteins 0.000 claims abstract description 15
- 241000700618 Vaccinia virus Species 0.000 claims description 47
- 239000000427 antigen Substances 0.000 claims description 23
- 108091007433 antigens Proteins 0.000 claims description 21
- 102000036639 antigens Human genes 0.000 claims description 20
- 108020004414 DNA Proteins 0.000 claims description 18
- 241000223960 Plasmodium falciparum Species 0.000 claims description 15
- 206010035500 Plasmodium falciparum infection Diseases 0.000 claims description 14
- 108010052285 Membrane Proteins Proteins 0.000 claims description 6
- 101710132601 Capsid protein Proteins 0.000 claims description 5
- 101710094648 Coat protein Proteins 0.000 claims description 5
- 101710125418 Major capsid protein Proteins 0.000 claims description 5
- 101710141454 Nucleoprotein Proteins 0.000 claims description 5
- 101710083689 Probable capsid protein Proteins 0.000 claims description 5
- 102000053602 DNA Human genes 0.000 claims description 4
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 claims description 4
- 108060003951 Immunoglobulin Proteins 0.000 claims description 4
- 102000018358 immunoglobulin Human genes 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 208000002672 hepatitis B Diseases 0.000 claims description 2
- 102400000368 Surface protein Human genes 0.000 claims 1
- 238000002255 vaccination Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 69
- 101710137302 Surface antigen S Proteins 0.000 description 68
- 108090000623 proteins and genes Proteins 0.000 description 47
- 206010046865 Vaccinia virus infection Diseases 0.000 description 25
- 208000007089 vaccinia Diseases 0.000 description 25
- 150000001413 amino acids Chemical class 0.000 description 24
- 102000004169 proteins and genes Human genes 0.000 description 24
- 241000283973 Oryctolagus cuniculus Species 0.000 description 23
- 235000018102 proteins Nutrition 0.000 description 23
- 235000001014 amino acid Nutrition 0.000 description 20
- 239000013612 plasmid Substances 0.000 description 20
- 239000012634 fragment Substances 0.000 description 19
- 230000003053 immunization Effects 0.000 description 16
- 238000002649 immunization Methods 0.000 description 12
- 239000013598 vector Substances 0.000 description 11
- 238000000034 method Methods 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 108091034117 Oligonucleotide Proteins 0.000 description 9
- 238000010367 cloning Methods 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- KQPKMEYBZUPZGK-UHFFFAOYSA-N 4-[(4-azido-2-nitroanilino)methyl]-5-(hydroxymethyl)-2-methylpyridin-3-ol Chemical group CC1=NC=C(CO)C(CNC=2C(=CC(=CC=2)N=[N+]=[N-])[N+]([O-])=O)=C1O KQPKMEYBZUPZGK-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 101001111984 Homo sapiens N-acylneuraminate-9-phosphatase Proteins 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 102100023906 N-acylneuraminate-9-phosphatase Human genes 0.000 description 6
- 229920004929 Triton X-114 Polymers 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000012286 ELISA Assay Methods 0.000 description 5
- 102000018697 Membrane Proteins Human genes 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 230000005847 immunogenicity Effects 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 244000045947 parasite Species 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 108091033380 Coding strand Proteins 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 102000005936 beta-Galactosidase Human genes 0.000 description 4
- 108010005774 beta-Galactosidase Proteins 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 239000012362 glacial acetic acid Substances 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 238000003119 immunoblot Methods 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 108091036060 Linker DNA Proteins 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 101150003725 TK gene Proteins 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000001524 infective effect Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 230000003252 repetitive effect Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 3
- 210000003934 vacuole Anatomy 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 2
- 101150065425 7.5K gene Proteins 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 101710193484 S-antigen protein Proteins 0.000 description 2
- 239000012722 SDS sample buffer Substances 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 239000002198 insoluble material Substances 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 102100022717 Atypical chemokine receptor 1 Human genes 0.000 description 1
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
- 101100328086 Caenorhabditis elegans cla-1 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 101710117490 Circumsporozoite protein Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102100036263 Glutamyl-tRNA(Gln) amidotransferase subunit C, mitochondrial Human genes 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 description 1
- 101001001786 Homo sapiens Glutamyl-tRNA(Gln) amidotransferase subunit C, mitochondrial Proteins 0.000 description 1
- 101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical class CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 1
- -1 NANP amino acid Chemical class 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 244000180577 Sambucus australis Species 0.000 description 1
- 235000018734 Sambucus australis Nutrition 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 108010046722 Thrombospondin 1 Proteins 0.000 description 1
- 102100036034 Thrombospondin-1 Human genes 0.000 description 1
- 101900176279 Vaccinia virus Surface antigen S Proteins 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229950004398 broxuridine Drugs 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 101150026451 csp gene Proteins 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000012973 diazabicyclooctane Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 229940042743 immune sera Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000000464 low-speed centrifugation Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 244000000040 protozoan parasite Species 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 210000001563 schizont Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 210000003046 sporozoite Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Definitions
- This invention relates to a recombinant virus, and in particular it relates to a recombinant vaccinia virus which has been modified to optimize the immunogenicity of foreign immunogenic polypeptides 5 expressed thereby.
- recombinant virus denotes infective virus which has been genetically modified by incorporation of 10 foreign genes or genetic material into the virus genome. The modified virus then expresses the foreign gene in the form of a "foreign" polypeptide on infection of a cell by the recombinant virus.
- recombinant vaccinia virus has a corresponding meaning.
- the foreign viral antigen which is now expressed by the vaccinia virus is in a near normal situation and its processing, modification, transport and final localization on the surface of the infected cell may be very similar to that in a normal infection.
- herpes simplex glycoprotein D (Paoletti et al, 1984; Cremer et al, 1985) , hepatitis B surface antigen (Smith et al, 1983; Moss et al, 1984) , vesicular stomatitis virus glycoprotein G, and influenza virus hemagglutinin (Smith et al, 1983; Panicali et al, 1983) genes are inserted into recombinant vaccinia virus, live recombinant viruses can be used to immunize animals against infection.
- the present invention provides in one aspect, a recombinant virus, characterised in that it includes a coding sequence for a hybrid polypeptide, said hybrid polypeptide comprising _at least one immunogenic polypeptide segment which is foreign to the virus or virus infected cells in association with a surface or membrane-associated polypeptide segment to locate said hybrid polypeptide on or at the surface of virus infected cells.
- this invention provides a recombinant vaccinia virus, characterised in that it includes a coding sequence for a hybrid polypeptide, said hybrid polypeptide comprising at least one immunogenic polypeptide segment which is foreign to vaccinia virus or vaccinia virus infected cells, in association with a surface or membrane-associated polypeptide segment to locate said hybrid polypeptide on or at the surface of vaccinia virus infected cells.
- this invention provides a DNA molecule comprising a coding sequence for a hybrid polypeptide, said hybrid polypeptide comprising at least one immunogenic polypeptide segment which is foreign to vaccinia virus or vaccinia virus infected cells in association with a surface or membrane-associated polypeptide segment to locate said hybrid polypeptide on or at the surface of vaccinia virus infected cells.
- hybrid polypeptide comprising at least one immunogenic polypeptide segment which is foreign to vaccinia virus or vaccinia virus infected cells in association with a surface or membrane-associated polypeptide segment to locate said hybrid polypeptide on or at the surface of vaccinia virus infected cells.
- the present invention is illustrated by way of example by the expression of a hybrid polypeptide based on the secreted repetitive plasmodial antigen (the S-antigen) in a recombinant vaccinia virus.
- the S-antigen proteins of Plasmodiu falciparum are secreted by the parasite into the space which separates the limiting membrane of the dividing parasites and the inner membrane of the red blood cell initially formed during the invagination process accompanying the parasite invasion of the red blood cell and subsequently elaborated during parasite growth.
- Immunogold electromicroscopy indicates that this space, known as the parasitophorous vacuole, is filled with
- a primary aim in the work leading to the present invention was to investigate the use of the live recombinant vaccine virus in the delivery of plasmodial blood-stage antigens to immunize animals and to compare the immune responses to those obtained using peptides generated by recombinant DNA techniques or synthesized chemically.
- a theoretical advantage of the live viral delivery approach is that it should better stimulate the cellular arm of the immune system which may be of prime importance in the efficacy of anti-parasitic vaccines.
- the mouse im unoglobulin gene has been used to provide the sequences necessary for the expression of the immunogenic polypeptide on the infected cell surface.
- Figure 1 illustrates the construction of transfection plasmids containing the deleted S-antigen gene of the FCQ27/PNG (FC27) isolate of P.falciparum.
- (a) shows the structure of the genomic copy of the FC27 S-antigen gene with sequences encoding a signal peptide (dark shading) and approximately 100 copies of the 11 amino acid repeating peptide sequence shown beneath the gene.
- the S-antigen gene is located immediately downstream from the vaccinia virus 7.5K gene promoter and is flanked on both sides by vaccinia virus TK gene sequences as shown in (c) .
- a hybrid S-antigen gene containing an immunoglobulin transmembrane sequence (hatched) and intracellular domain (dotted) was constructed from pV8 to generate the plasmid pVA20 which is shown in part in (d) .
- Figure 2 is a Western blot analysis of S-antigen produced by BSC1 cells infected with the recombinant vaccinia virus V8 (lanes 2 and 3) compared with that produced by E.coli under the control of the p ⁇ " C9 ⁇ -galactosidase promoter (lane 1) .
- Lanes 2 and 3 show the relative amounts of S-antigen associated with the virus infected cells and the culture medium at 48 hours after infection. The culture medium was centrifuged at 12,000g for 3mins prior to analysis. Filters were probed with a rabbit antisera recognizing only the 11 amino acid repeat portion of the S-antigen.
- Figure 3 shows the time course of the synthesis and secretion of S-antigen in vaccinia infected BSC1 cell monolayers.
- Cells were infected for lhr at lpfu/cell. At this time the innoculum was removed and fresh medium was added.
- a sample of the culture medium was taken at various times after infection and subjected to centrifugation at 12,000g for 3mins. The supernatent from this centrifugation was taken for analysis. The remaining cells and medium were scraped from the dishes and quantitatively transferred to a fresh tube. Following sonication a sample was taken and dissolved in SDS sample buffer for analysis by SDS/PAGE. Equal fractions of each sample were analysed. Filters were probed with a rabbit antisera which specifically recognized the 11 amino acid repeat of the S-antigen.
- Figure 4 is a diagramatic representation of the steps used in the subcloning of the mouse membrane IgG transmembrane sequence into the Sphl site at the 3 ' end of the FC27 S-antigen gene.
- a 186bp Haelll fragment encoding the transmembrane, intracellular domain and a portion of the hinge region was isolated from the ⁇ l cDNA clone described by Tyler et al, 1982.
- Sphl linker DNA was added to the ends of this fragment which after Sphl digestion, was cloned into the Sphl site of the S-antigen gene clone pFC27 Aha2 to generate the new clone pA20.
- the sequence at the junction of the S-antigen gene and the immunoglobulin gene is shown at the bottom and indicates the new amino acid sequence at the junction.
- the amino acids alanine and proline, indicated with an asterisk, are not present in either of the parental proteins as they are generated by the Sphl linker DNA sequences.
- Six amino acids of the extracellular domain of the immunoglobulin gene are present in the new hybrid protein.
- Figure 5 shows that the S-antigen produced by cells infected with the VA20 recombinant virus is no longer secreted.
- Samples of infected cells and culture medium were collected as described in Figure 3 48 hours after infection with either V8 or VA20 recombinant virus at lpfu/cell. The total amount of S-antigen appears to remain the same, however very little is secreted into the medium in the case of VA20 infected cells.
- Westerns were probed with a rabbit anti-FC27 S-antigen repeat antisera.
- Figure 6 BSC-1 cells infected for 48hrs with either the V8 _or VA20 recombinant virus were solubilized in 0.05% Triton X114 for lhr at 4°C.
- Figure 7 shows indirect immunofluorescence of BSGl cells infected 18hrs earlier with recombinant virus VA20 (A and C) or V8 (B and D) .
- Cells were either fixed prior to staining (A and B) to permeabilize the cells ' and allow detection of intracellular S-antigen or fixed after staining to detect S-antigen localized on the surface of the infected cells (C and D) .
- Figure 8 sets out the antibody titres of mice sera assayed at 3 weeks after a single IP immunization with 1x10 PFU of the V8 or VA20 recombinant virus.
- Ninety-six well microtitre trays were coated with a FC27 S-antigen repeat/3-galactosidase fusion polypeptide preparation at a predetermined optimal concentration of 3 ⁇ g/ml.
- Pre-immune sera were serial diluted to determine the dilution at which half maximal absorbance was reached. Thse values are plotted for both the BALB/c.H-2 and 129/J strains of mice used.
- Figure 9 is a plot of the absorbance values obtained in a typical ELISA assay of rabbit antisera taken at one to five weeks after a single ID injection g of 10 PFU of live recombinant virus VA20.
- Sera were J assay for both anti S-antigen antibodies as described in Figure 8 at a standard dilution of 1:320 of the sera (dotted line) or for anti-vaccinia antibodies using plates coated with BPL inactivated vaccinia virus at a standard dilution of 1:2580 of the serum (solid lines).
- - (B) shows the absorbance values obtained in a ELISA assay in which individual rabbit antisera were assayed for anti S-antigen antibodies at 2 weeks after
- Recombinants were selected in which the S-antigen gene was inserted in the correct orientation 3' to the vaccinia 7.5K protein early gene promotor and flanked on either side by the 5' and 3' ends of the vaccinia virus TK gene sequences of the plasmid vector.
- This new construct, pV8, was used to transfect CV1 cells infected with wild type vaccinia virus giving rise to the recombinant vaccinia virus V8, containing the S-antigen gene.
- the addition of the mouse membrane immunoglobulin transmembrane sequence to the S-antigen gene was used to transfect CV1 cells infected with wild type vaccinia virus giving rise to the recombinant vaccinia virus V8, containing the S-antigen gene.
- a 186bp Haelll fragment containg sequences encoding six amino acids of the hinge region, 26 amino acids of the transmembrane domain and 28 amino acids of the intracellular domain of the mouse IgG, immunoglobulin was isolated from the ⁇ l cDNA clone described by Tyler et al (1982). Sphl linker DNA with the sequence 5'-CCGCATGCGG-3' was then ligate to the Haelll fragment, digested with Sphl and cloned into the unique Sphl site located 65bp from the .3' end of the S-antigen gene in the subclone pFC Aha2.
- This plasmid DNA was used to transfect vaccinia infected CV1 cells to produce the recombinant vaccinia virus VA20.
- Recombinant viruses con ⁇ taining the S-antigen genes were screened for the presence of DNA by dot blot analysis or for the production of S-antigen which was detected by a high titre polyclonal antisera, R210, raised by immunizing rabbits with a ⁇ -galactosidase fused polypeptide from clone Agl6 (Coppel et al, 1983) con taining 23 copies of the 11 amino acid FC27 S-antigen repeating polypeptid Expression of S-antigen in recombinant vaccinia infected cells.
- Confluent monolayers of BSC-1 cells were routinely infected at lpfu/cell with purifi recombinant virus and allowed to incubate at 37°C for 18-48hrs at which ti the infected cells and/or the supernatant were harvested and dissolved in SDS, sample buffer and boiled. Samples were then analysed by immunoblotti 0; and probed with a rabbit anti S-antigen antisera, R210 which recognizes th repeating epitope of the S-antigen molecule.
- Triton X114 partitioning Recombinant vaccinia infected cells were dissol in 0.5% Triton X114 in PBS for lhr at 4°C. Following centrifugation at 20 rpm to remove nuclei in the Triton X114 soluble material was layered over 5 cushion of 6% Triton in 0.06% sucrose/PBS and then the temperature was rai to 37°C. The cloudy suspension of insoluble material was removed by centr fugation at 37°C. This fraction which is referred to as the Triton X114 pellet, should contain the integral membrane proteins by virtue of the greater affinity of their hydrophobic transmembrane sequences for the Trit Q , X114 detergent which becomes insoluble at elevated temperature (Bordier, 1981).
- BSC-1 cells were grown onto sterile glass covers!ips for a period of 6hrs after which they were infected at 0.5pfu/cell with either the V8 or VA20 recombinant viruses or TK nonreco binant virus as control. After 18hrs, coverslips were rinsed in cold PBS and then stained immediately with rabbit anti-S-antigen antisera followed by FITC conjugate sheep anti-rabbit antibodies. Cells were then post fixed in cold 95% ethanol:5% glacial acetic acid prior to mounting under glycerol and visualization by fluorescence microscopy.
- mice within a few days of the first immunization, reaching a size of approximate 1 to 1.5cm in diameter. Occasionally these lesions ulcerated. Lesions were no longer apparent after two weeks. Rabbits were bled at weekly intervals and the sera analysed for anti-S-antigen or anti-vaccinia antibodies in an ELISA assay. Age and weight-matched inbred mice of various strains were
- FC27 S-antigen gene of P.falciparum is expressed in recombinant vaccinia
- the recombinant virus was indeed the correct length (data not shown).
- abnormal SDS binding characteristics result in this aberrant MW determination on SDS/PAGE.
- S-antigen appears to be synthesized in recombinant vaccinia infected cells under the control of vaccinia promotor elements.
- the S-antigen is secreted from vaccinia infected cells
- Monolayers of BSC1 cells were infected with purified recombinant virus V8. After Bit, the virus innoculum was replaced with fresh medium and then at various times the cells and culture medium were harvested, separated by centrifugation and subjected to analysis by immunoblotting. Detectable
- Triton X114 partition experiments (Bordier, 1981) were performed to test if, by this criteria, the hybrid S-antigen containing the transmembran segment behaved as a typical integral membrane protein. Indeed, whereas the V8 protein behaves exclusively as a hydrophilic soluble protein, the majority of the VA20 protein partitioned into the detergent phase ( Figure 6 indicating that the hydrophobic transmembrane sequence had converted the soluble S-antigen protein into a membrane-associated protein.
- BSC-1 cells infected with either VA20 or V8 recombinant virus were subjected to indirec immunofluroescence 18hrs after infection.
- Figure 9a shows that the anti S-antigen Ab titres in the VA20 immunized rabbits peaked two weeks after immunization despite the fact that anti- vaccinia antibody titres continued to climb over the next three week period The same was true of the rabbit responses to the V8 recombinant although here the responses were very small and difficult to measure.
- Figure 9B shows that the anti S-antigen Ab titres in the VA20 immunized rabbits peaked two weeks after immunization despite the fact that anti- vaccinia antibody titres continued to climb over the next three week period The same was true of the rabbit responses to the V8 recombinant although here the responses were very small and difficult to measure.
- Figure 9B shows that the anti S-antigen Ab titres in the VA20 immunized rabbits peaked two weeks after immunization despite the fact that anti- vaccinia antibody titres continued to climb over the next three week period The same was true of the rabbit responses to the V8 recombinant although here the responses were very small
- Example 1 is a specific example of a more general method by which biologically important molecules which, although themselves not surface antigen molecules, can be redirected to the surface of recombinant vaccinia virus-infected cells. This example also shows how crucial this surface localization of the antigen is for the induction of good immune responses to the foreign introduced antigen.
- the antigen chosen for Example 1, the malarial S-antigen has to date not been implicated as a potential vaccine candidate primarily because the immunodominant repeat portion of the molecule is remarkably variant. These repeating structures vary 5 enormously in their number, length and amino acid composition which greatly affects their immunological properties but not, it would seem, their behaviour as secreted proteins.
- the present Example illustrates that it is possible 0 to replace the S-antigen repeating epitope with an unrelated sequence which is- of importance as a vaccine molecule.
- These hybrid molecules containing in addition an appropriate trans-membrane anchoring sequence, should be, in many cases, as efficiently 5 transported to the surface of the recombinant virus-infected cell as is the hybrid S-antigen molecule described above.
- NANP Asn-Ala-Asn-Pro
- this Example is one example of an approach by which one can tailor an antigenic determinant into a "carrier" molecule designed to deliver this epitope to the surface of recombinant vaccinia virus infected cells.
- a murine retrovirus is also able to express the product of the hybrid VA20 gene on the surface of virus-infected mouse cells in culture demonstrating that this approach may be of general applicability to a variety of antigenic epitopes expressed in any of a number of "carrier" epitopes in a variety of recombinant viral vector systems.
- Figure 10 is a diagramatic representation of the manipulations required to delete the 33bp S-antigen repeating sequences from pVA20 and to replace them with sequences encoding 16, 32 and 48 copies of the 4 amino acid repeating epitope of the P.falciparum circumsporozoite coat protein.
- Figure 11 is a schematic representation of the
- P.falciparum circumsporozoite coat protein gene (at top) showing the sequence of the dominant 4 amino acid repeating unit, NANP.
- sequences of the synthetic oligonucleotides used in the synthesis of the new insert and (at bottom) the sequence of the 5" and 3' junction regions between the BamHl cut plasmid pLK8 (S-antigen sequences) and the new insert sequences.
- 6BP adaptor sequences shown in solid boxes at the 5' and 3' ends of the insert, the Sau3A sites flanking the insert and how a BamHl site is only regenerated at the 5' end of the insert.
- 5' and 3' refer to the ends of the coding strand of the insert DNA.
- Figure 12 shows double stranded DNA sequencing reactions of DNA from plasmids p6.44, p66.6 and p.666.34 containing 16, 32 and 48 copies, respectively, of the 12bp repeating sequence of the P.falciparum circumsporozoite protein. For clarity only the "A" ⁇ reactions are shown for the 3 constructs. At left is the sequence of the coding strand of the synthetic oligonucleotide used in the constructions with the sequence 5 '-AACVCCAACCC-3 ' . As can be seen, two pairs of A. doublets occur in each copy of the repeat.
- the : sequencing primer was a 17 nucleotide homologous to coding strand sequences located 20bp 5 ' to the BamHl site.
- Figure 13 is an immunoblot of proteins derived from recombinant virus-infected BSC-1 cells probed with an antisera (R516 anti NANP.,-K-LH) produced by immunizing rabbits with a 12 amino acid long synthetic peptide encoding 3 copies of the 4 amino acid squence NANP conjugated to KLH.
- This antiserum recognises polypeptides produced by cells infected with recombinant virus (V6.44) containing the -6.44 hybrid gene described above but not produced in a parallel experiment with cells infected with a similar construct containing unrelated sequences inserted at the BamHl site (V-control) .
- Molecular weights in Kdaltons are shown at right.
- the plasmid pLK8 contains the S-antigen gene with less than one full copy of the 33bp repeating sequence and with a unique BamHl site located within this remaining partial repeat sequence. It is into this site that appropriately engineered sequences encoding antigenic determinants can be cloned, thus neatly replacing the S-antigen repeating epitope.
- the incoming sequences in the situation described in this example would need to have BamHl "sticky ends" and to be engineered in such a way that the reading frame of the whole hybrid gene is maintained.
- the total length of the insert DNA should be an equal multiple of 3 base pairs and that the reading frame be in phase with the GAT codon of the GGATCC BamHl site at the 5 1 end of the (coding strand of the) insert. It is also believed that the epitope to be expressed should be repeated as many times as possible to maximize its immunogenicity even if this epitope is represented only once in the native antigen molecule.
- P.falciparum circumsporozoite coat protein has been chosen. It will be appreciated, however, that the same procedures could equally well be applied to the linear epitopes or the "mimotopes" of conformational epitopes of other antigen molecules.
- 5 *-AACGCCAACCCC-3 ' and 5 • -GGTTGGCGTTGG-3 ' were made on an Applied Biosystems oligonucleotide synthesiser and purified by HPLC. These were then kinased prior to annealing and ligation in the standard way.
- the oligonucleotides were designed so that the ends were complimentary in one orientation only, ensuring that only "head to tail” ligation of the double stranded monomers was possible.
- the ligated fragments were then size fractionated on a low gelling temperature agarose 5; gel and DNA molcules in the size range from 180 to 600bp were isolated and purified from the agarose.
- Recombinant bacterial clones containing the 12bp sequence were selected by colony hybridization using a
- Plasmid DNA was isolated from the positive clones and digested with restriction enzymes to determine the clones which contained the longest inserts. A number of these were then sequenced using the double stranded DNA 5
- the new 192b ⁇ insert in the hybrid gene p6.44 is flanked by Sau3A sites which allow the insert to be isolated and purified from the recombinant plasmid. However only one BamHl site at the 5 * of the coding j strand of the insert is regenerated in this hybrid (see figure 11) .
- the recombinant plasmid can be linearised with BamHl, phosphatase treated and ligated with the isolated 192bp Sau3A fragment. Plasmid DNA was prepared from the transformed bacteria resulting from 0 this cloning and digested with restriction enzymes to select clones with double (or triple) inserts. These were then sequenced to determine which were in the correct orientation and to confirm the predicted sequence.
- inserts containng 16(p6.44) , 32(p66.6) and 48(p666.34) copies of the 12bp repeat of the CSP gene have been poduced (see Q figures 10 and 12) .
- FIG. 13 shows a Western blot of proteins produced by V6.44 virus-infected mammalian BSC-1 cells probed with a rabbit antisera raised against a 12 amino acid long synthetic peptide comprising 3 copies of the NANP peptide.
- Isolate-specific S-antigen of Plasmodiu falciparum contains a repeated sequence of eleven amino acids. Nature 306, 751-756. Cremer, K.J. , Mackett, M. , Wohlenberg, C. , Notkins, A.L. and Moss, B. (1985 Vaccinia virus recombinant expressing herpes simplex virus type 1 glyc protein D prevents latent herpes in mice. Science 228, 737-740.
- Vaccinia virus A selectable eukaryotic cloning and expression vector. Proc.Natl.Acad.Sci.USA 79, 7415-7419. Mackett, M. , Smith, G.L. and Moss, B. (1984). General method for production and selection of infectious vaccinia virus reco binants expressing foreign genes. J.Virol. 49, 857-864. Moss, B. , Smith, G.L. , Gerin, J.L. and Purcell , R.H. (1984). Live recombin vaccinia virus protects chimpanzees against hepatitis B. Nature 311, 67-69. Panicali, D. and Paoletti, E. (1982).
- pox viruses as cloni vectors: Insertion of the thymidine kinase gene of herpes simplex viru into the DNA of infectious vaccinia virus. Proc.Natl.Acad.Sci.USA 79, 4927-4931.
- liver vaccines using genetically engineered pox viruses Biological activity of vaccinia virus recombinants expres ing the hepatitis B surface antigen and the herpes simplex glycoprotei D. Proc.Natl.Acad.Sci.USA 81, 193-197.
- mRNA for surface immunoglobulin ⁇ chains encodes a highly con served transmembrane sequence and a 28-residue intracellular domain. Proc.Natl.Acad.Sci.USA 79, 2008-2012. Valenzuela, P., Coit, D. , Medina-Selby, M.A. , Kuo, CH. , Van Nest, G. , Burk R.L. , Bull, P., Urdea, M.S. and Graves, P.V. (1985). Antigen engineer ing in yeast: Synthesis and assembly of hybrid hepatitis B surface antigen-herpes simplex 1 gD particles. Biotechnology 3, 323-326.
Abstract
Un virus recombinant, tel qu'un virus recombinant de vaccination, comprend une séquence de codage d'un polypeptide hybride comprenant au moins un segment polypeptidique immunogène étranger au virus ou aux cellules infectées par le virus associé à un segment polypeptidique superficiel ou lié à la membrane servant à situer le polypeptide hybride sur ou au niveau de la surface des cellules infectées par des virus.A recombinant virus, such as a recombinant vaccination virus, comprises a coding sequence for a hybrid polypeptide comprising at least one immunogenic polypeptide segment foreign to the virus or to cells infected with the virus associated with a surface polypeptide segment or linked to the membrane for locating the hybrid polypeptide on or at the surface of cells infected with viruses.
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPH219885 | 1985-08-29 | ||
AU2198/85 | 1985-08-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0244427A1 true EP0244427A1 (en) | 1987-11-11 |
EP0244427A4 EP0244427A4 (en) | 1989-04-27 |
Family
ID=3771250
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19860905164 Withdrawn EP0244427A4 (en) | 1985-08-29 | 1986-08-29 | Recombinant virus. |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP0244427A4 (en) |
JP (1) | JPS63500637A (en) |
KR (1) | KR880700073A (en) |
AU (1) | AU594087B2 (en) |
DK (1) | DK219187D0 (en) |
ES (1) | ES2002128A6 (en) |
FI (1) | FI871885A (en) |
IL (1) | IL79880A0 (en) |
NZ (1) | NZ217400A (en) |
WO (1) | WO1987001386A1 (en) |
ZA (1) | ZA866582B (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5182211A (en) * | 1987-08-07 | 1993-01-26 | Institut Pasteur | Plasmid vectors encoding a protein of a picornavirus |
EP0398944A4 (en) * | 1988-02-05 | 1991-09-11 | Commonwealth Scientific And Industrial Research Organisation | Gene expression system (particularly for rotavirus vp7 protein) involving a foreign signal peptide and optionally a transmembrane anchor sequence |
FR2663228A2 (en) * | 1989-09-29 | 1991-12-20 | Agronomique Inst Nat Rech | Immunising composition against Newcastle disease and method of preparation |
US8101189B2 (en) | 2002-07-05 | 2012-01-24 | Folia Biotech Inc. | Vaccines and immunopotentiating compositions and methods for making and using them |
CA2434000C (en) | 2002-07-05 | 2012-07-17 | Denis Leclerc | Adjuvant viral particle |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1984002917A1 (en) * | 1983-01-28 | 1984-08-02 | Inst Medical W & E Hall | EXPRESSION OF PLASMODIUM FALCIPARUM POLYPEPTIDES FROM CLONED cDNA |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2442271A1 (en) * | 1978-11-27 | 1980-06-20 | Pasteur Institut | VECTOR FOR THE INSERTION OF A PROKARYOTE OR EUKARYOTE GENE, AND EXCRETION OF THE EXPRESSED PROTEIN |
US4603112A (en) * | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
US4593002A (en) * | 1982-01-11 | 1986-06-03 | Salk Institute Biotechnology/Industrial Associates, Inc. | Viruses with recombinant surface proteins |
AU570940B2 (en) * | 1982-11-30 | 1988-03-31 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Process for producing poxvirus recombinants for expression offoreign genes |
EP0162738A1 (en) * | 1984-04-09 | 1985-11-27 | MOLECULAR GENETICS RESEARCH & DEVELOPMENT LIMITED PARTNERSHIP | Production of pseudorabies virus subunit vaccines |
FR2563434B1 (en) * | 1984-04-25 | 1986-07-25 | Transgene Sa | Rabies vaccine and process for its preparation |
-
1986
- 1986-08-28 IL IL79880A patent/IL79880A0/en unknown
- 1986-08-29 AU AU63701/86A patent/AU594087B2/en not_active Ceased
- 1986-08-29 ES ES8601549A patent/ES2002128A6/en not_active Expired
- 1986-08-29 NZ NZ217400A patent/NZ217400A/en unknown
- 1986-08-29 WO PCT/AU1986/000256 patent/WO1987001386A1/en not_active Application Discontinuation
- 1986-08-29 ZA ZA866582A patent/ZA866582B/en unknown
- 1986-08-29 EP EP19860905164 patent/EP0244427A4/en not_active Withdrawn
- 1986-08-29 JP JP61505157A patent/JPS63500637A/en active Pending
-
1987
- 1987-04-20 KR KR1019870700378A patent/KR880700073A/en not_active Application Discontinuation
- 1987-04-29 DK DK219187A patent/DK219187D0/en not_active Application Discontinuation
- 1987-04-29 FI FI871885A patent/FI871885A/en not_active IP Right Cessation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1984002917A1 (en) * | 1983-01-28 | 1984-08-02 | Inst Medical W & E Hall | EXPRESSION OF PLASMODIUM FALCIPARUM POLYPEPTIDES FROM CLONED cDNA |
Non-Patent Citations (3)
Title |
---|
MOLECULAR AND CELLULAR BIOLOGY, vol. 6, no. 9, September 1986, pages 3191-3199, American Society for Microbiology; C.J. LANGFORD et al.: "Anchoring a secreted plasmodium antigen on the surface of recombinant vaccinia virus-infected cells increases its immunogenicity" * |
NEW APPROACHES TO IMMUNIZATION: DEVELOPING VACCINES AGAINST PARASITIC, BACTERIAL AND VIRAL DISEASES; CONFERENCE ON VACCINES 86, pages 145-148, Cold Spring Harbor Laboratory, New York, US; C.J. LANGFORD et al.: "Antigens of the asexual blood stages of Plasmodium falciparum and their expression in recombinant vaccinia virus" * |
See also references of WO8701386A1 * |
Also Published As
Publication number | Publication date |
---|---|
FI871885A0 (en) | 1987-04-29 |
FI871885A (en) | 1987-04-29 |
IL79880A0 (en) | 1986-11-30 |
AU6370186A (en) | 1987-03-24 |
ZA866582B (en) | 1987-04-29 |
NZ217400A (en) | 1989-09-27 |
DK219187A (en) | 1987-04-29 |
KR880700073A (en) | 1988-02-15 |
AU594087B2 (en) | 1990-03-01 |
EP0244427A4 (en) | 1989-04-27 |
WO1987001386A1 (en) | 1987-03-12 |
DK219187D0 (en) | 1987-04-29 |
JPS63500637A (en) | 1988-03-10 |
ES2002128A6 (en) | 1988-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Langford et al. | Anchoring a secreted plasmodium antigen on the surface of recombinant vaccinia virus-infected cells increases its immunogenicity | |
Barr et al. | Recombinant Pfs25 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in experimental animals. | |
JP3051130B2 (en) | Recombinant coccidiosis vaccines | |
US6958235B1 (en) | Recombinant protein containing a C-terminal fragment of plasmodium MSP-1 | |
JPH08505768A (en) | Novel proteinaceous particles | |
US6551586B1 (en) | Malaria vaccine based upon the addition of a MSA1 peptide | |
US5403581A (en) | Coccidiosis vaccines | |
Pye et al. | Failure of recombinant vaccinia viruses expressing Plasmodium falciparum antigens to protect Saimiri monkeys against malaria | |
US6933130B1 (en) | Recombinants process for preparing a complete malaria antigen, gp190/MSP1 | |
AU594087B2 (en) | Recombinant vaccinia virus sxpresses hybrid polypeptides on virus infected cell surface | |
PH27079A (en) | Immunogenic recombinant yeast expression product and method for purifying it | |
US5217898A (en) | Expression of the P. falciparum transmission-blocking antigen in yeast | |
AU709479B2 (en) | Recombinant attentuated canrypox ALVAC virus expression vectors containing heterologous DNA segments encoding malarial gene products | |
WO1988002757A1 (en) | Hybrid proteins or polypeptides | |
US20040063190A1 (en) | Preparation and usage of plasmodium fusion antigen | |
US20060127413A1 (en) | Recombinant mva strains as potential vaccines against p. falciparum malaria | |
CZ337897A3 (en) | Modified polypeptides exhibiting increased immunogenic property | |
EP0474891A1 (en) | Vectors for expression of malarial antigens on the surface of Salmonella vaccine strains | |
US5853739A (en) | Transmission-blocking vaccine against malaria | |
US5393523A (en) | Plasmodium falciparum vaccine comprising a recombinant histidine-rich protein-HRP-II | |
Yang et al. | Addition of the MSA1 signal and anchor sequences to the malaria merozoite surface antigen 1 C-terminal region enhances immunogenicity when expressed by recombinant vaccinia virus | |
EP0250261A1 (en) | Vaccines containing epitopes of both the CSP and a blood stage antigen of a plasmodium parasite | |
NO871737L (en) | RECOMBINANT VIRUS. | |
JPH10298104A (en) | Vaccine | |
Barr et al. | Recombinant Pfs25 Protein of Plasmoch'um |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19870502 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LI LU NL SE |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 19890427 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 19901025 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: SARAMANE PTY. LTD. |
|
18D | Application deemed to be withdrawn |
Effective date: 19920303 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: LANGFORD, CHRISTOPHER, JOHN Inventor name: EDWARDS, STIRLING, JOHN |